Bcl6 Antibody

Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the recombinant Bcl6 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Amino acids 256-389 were used as the immunogen for the recombinant Bcl6 antibody.

This recombinant Bcl6 antibody is available for research use only.

Nuclear

Protein G affinity chromatography

Human

P41182